Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer

Wang, Ying; Liu, Ping; Xu, Yan; Zhang, Weihao; Tong, Lina; Zhi, Guo; Ni, Hong

doi:10.1007/s00280-014-2622-6

Cited by 55 publications

(49 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One explanation is that NLR and PLR may also increase secondarily as systemic inflammation increases [7]. These factors are expected to detect advanced-stage disease and thereby predict prognosis similar to serum CA-125 levels in early-stage EOC [1333]. …”

Section: Discussionmentioning

confidence: 99%

“…On the other hand, clinical biomarkers using systemic inflammation and coagulation has been suggested to be useful to predict prognosis of EOC with the advantage of being clinically easily measured [9]. In particular, systemic inflammation leading to secondary hematological changes has been shown in various types of malignancies [1011], and changes, such as the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR), have been investigated as prognostic biomarkers in EOC [1213]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis

Luo

Kim

et al. 2017

J Gynecol Oncol

View full text Add to dashboard Cite

ObjectiveTo evaluate the effect of elevated plasma fibrinogen levels on the prognosis of epithelial ovarian cancer (EOC).MethodsWe reviewed the data of 217 patients with advanced-stage EOC between 2000 and 2012, and investigated the prognostic role of elevated plasma fibrinogen levels compared with serum CA-125 levels, neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR). For further evaluation, we performed a meta-analysis using 5 cohort studies published to July 2015, including our cohort study after a literature review.ResultsAmong the four biomarkers, only plasma fibrinogen levels >485.2 mg/dL were correlated with impaired progression-free survival (PFS) and overall survival (OS) (median, 13.9 vs. 20.3 months and 42.2 vs. 55.4 months; p<0.010). Elevated plasma fibrinogen levels were an independent factor for poor PFS with marginal significance and OS (adjusted hazard ratios [HRs]=1.389 and 1.581; 95% confidence intervals [CIs]=0.979–1.972 and 1.032–2.423, respectively). Furthermore, crude and subgroup meta-analyses demonstrated that elevated plasma fibrinogen levels were associated with impaired PFS and OS in patients with all stage EOC.ConclusionElevated plasma fibrinogen levels be more important for predicting survival than serum CA-125 levels, NLR and PLR in patients with EOC, in particular, advanced-stage disease. Moreover, it may be related to poor prognosis of EOC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis

Luo

Kim

et al. 2017

J Gynecol Oncol

View full text Add to dashboard Cite

show abstract

“…Recently, PLRs have been used as an independent predictor of survival in patients with ovarian cancer [13]. In addition, the use of NLR could not only apply as a prognostic marker, but also aid in treatment choices in ovarian cancer [12,14,16,17]. Furthermore, variation in the reported NLR threshold used to assign patients to high-risk or low-risk cohorts complicates the application of a single NLR determination for patient’s prognostic prediction.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma

Zhang

Lü

Lu³

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Chronic inflammation is a well-known epidemiologic factor of ovarian clear cell carcinomas (OCCC), but has an uncertain role in prognosis. We developed a systemic inflammation score (SIS) based on preoperative serum albumin and neutrophil-to-lymphocyte ratio (NLR) for predicting progression-free survival (PFS) and overall survival (OS) in OCCC patients. A retrospective review was performed in 155 patients with OCCC undergoing primary debulking and chemotherapy at a single institute between 1995 and 2010. Cox regression models were fitted to analyze the effect of prognostic factors on PFS and OS. Harrell’s concordance index was calculated to assess predictive accuracy. The SIS consisting of serum albumin and NLR was retained as an independent indicator adjusting for traditional clinicopathological features. A high SIS was significantly associated with aggressive tumor behavior, platinum resistance, and served as an independent predictor of reduced PFS (P = 0.006) and OS (P = 0.019). The SIS had a good discrimination ability for the predictive PFS (c-index = 0.712) and OS (c-index = 0.722). We have developed a system inflammation score for predicting prognosis of OCCC patients, which may help stratify patients for postsurgical management.

show abstract

“…Risk of malignancy index (RMI) which includes ca125, ultrasound findings and menopausal status have been developed for this purpose. The increasing evidences emphasize the importance of inflammation in the initiation, promotion, invasion and metastasis of cancer [5]. It was found that neutrophils increased and lymphocytes relatively decreased as a result of the systemic inflammatory response [8].…”

Section: Discussionmentioning

confidence: 99%

“…As preoperative inflammatory markers, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been suggested to be useful for discriminating malignant and benign ovarian tumors. NLR and PLR are noninvasive, easily measured, universally known and cost-effective markers [5–7]. …”

Section: Introductionmentioning

confidence: 99%

Does preoperative neutrophil to lymphocyte or platelet to lymphocyte ratios have a role in predicting borderline ovarian tumors?

et al. 2016

View full text Add to dashboard Cite

Backgroundto investigate the value of using preoperative neutrophil to lymphocyte and platelet to lymphocyte levels in the patients of borderline ovarian tumors.MethodsDuring the period between January 2002 and December 2015, the pathology reports and archival files of the Gynecologic Oncology Department of Çukurova University Medical Hospital and the Gynecologic Oncology Department of Dumlupınar University, Evliya Çelebi Education and Research Hospital were retrospectively reviewed, and 144 patients of borderline ovarian tumor (as the study group) and 123 patients of serous cystadenoma (as the control group) were determined for eligibility in this study. Data regarding age, menopausal status, preoperative ultrasound findings, ca125 and complete blood counts were reviewed. Neutrophil to lymphocyte and platelet to lymphocyte ratios were calculated and these parameters were statistically compared between the groups.ResultsThere was a statistically significant difference between the groups according to neutrophil count, platelet count, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio; in addition to age, ca125 and preoperative ultrasound findings.ConclusionsIt seems that neutrophil to lymphocyte and platelet to lymphocyte ratios are useful in predicting borderline ovarian tumors, preoperatively. However, further prospective studies are needed.

show abstract

Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer

Cited by 55 publications

References 23 publications

Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis

Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis

Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma

Does preoperative neutrophil to lymphocyte or platelet to lymphocyte ratios have a role in predicting borderline ovarian tumors?

Contact Info

Product

Resources

About